Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Efficacy and Safety × Clear all
NCT04518501 2024-12-04

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Women's Hospital School Of Medicine Zhejiang University

Phase 1/2 Recruiting
50 enrolled

Efficacy and Safety

NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

NCT04284215 2020-02-25

Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC

Guizhou Medical University

Phase NA Unknown
68 enrolled

Efficacy and Safety

NCT03660761 2019-04-16

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Shandong Cancer Hospital and Institute

Phase 2 Completed
25 enrolled

Efficacy and Safety

NCT03255343 2017-08-21

ImDendrim

French Association for the Advancement Medical Research

Phase NA Unknown
10 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡